Eli Lilly CEO aims to start testing coronavirus cure 'this summer' [CNBC]
Vir Biotechnology, Inc. (VIR)
Company Research
Source: CNBC
Eli Lilly The pharmaceutical giant on Thursday announced that it has teamed up with the privately held AbCellera Biologics to co-develop a medicine for COVID-19, the disease caused by the virus that has sickened more than 137,000 people across the world and at least 1,700 in the U.S. as of Friday. "The speed at which [pharma research] is unfolding is unprecedented in our industry. Literally, AbCellera started this work 11 days ago," Ricks said in a phone interview with Jim Cramer Mad Money To begin developing a cure, AbCellera screened and isolated antibodies of the first U.S. patients to recover from the illness, Ricks explained. Eli Lilly will assist in replicating the antibodies that may respond to the virus to produce and manufacture a drug, he said. "We're partnering to find the best one, scale up production and bring it to the marketplace," he said. A potential COVID-19 treatment may require more than one medicine for the most ill patients, Ricks added. He expects that the drug,
Show less
Read more
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis DeltaBusiness Wire
- Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager ProgramsBusiness Wire
VIR
Earnings
- 10/31/24 - Miss
VIR
Sec Filings
- 12/4/24 - Form 4
- 12/2/24 - Form 144
- 11/18/24 - Form 4
- VIR's page on the SEC website